Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp)

Fredrik Barrenas; Richard R Green; Matthew J Thomas; G Lynn Law; Sean C Proll; Flora Engelmann; Ilhem Messaoudi; Andrea Marzi; Heinz Feldmann; Michael G Katze

doi:10.1128/CVI.00733-14

Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp)

Clin Vaccine Immunol. 2015 Mar;22(3):354-6. doi: 10.1128/CVI.00733-14. Epub 2015 Jan 14.

Authors

Affiliations

¹ Department of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
² Department of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA.
³ Vaccine and Gene Therapy Institute, Beaverton, Oregon, USA.
⁴ Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA.
⁵ Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA.
⁶ Department of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA honey@uw.edu.

Abstract

Vesicular stomatitis virus expressing Zaire Ebola virus (EBOV) glycoprotein (VSVΔG/EBOVgp) could be used as a vaccine to meet the 2014 Ebola virus outbreak. To characterize the host response to this vaccine, we used mRNA sequencing to analyze peripheral blood mononuclear cells (PBMCs) from cynomolgus macaques after VSVΔG/EBOVgp immunization and subsequent EBOV challenge. We found a controlled transcriptional response that transitioned to immune regulation as the EBOV was cleared. This observation supports the safety of the vaccine.

MeSH terms

Animals
Antibodies, Viral / blood
Democratic Republic of the Congo
Ebola Vaccines / immunology*
Ebolavirus / genetics
Ebolavirus / immunology*
Ebolavirus / pathogenicity
Gene Expression
Hemorrhagic Fever, Ebola / immunology*
High-Throughput Nucleotide Sequencing
Leukocytes, Mononuclear / immunology*
Leukocytes, Mononuclear / metabolism
Macaca fascicularis
Sequence Analysis, RNA
Time Factors
Transcriptome
Vaccines, Synthetic / immunology
Vesiculovirus / immunology*
Viral Envelope Proteins / immunology*

Substances

Antibodies, Viral
Ebola Vaccines
Vaccines, Synthetic
Viral Envelope Proteins
envelope glycoprotein, Ebola virus

Grants and funding

P51 OD010425/OD/NIH HHS/United States